Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q3 2021 · 10-Q
Revenue$7.65M$7.65M+44.1% vs Q3 2020 Net Income-$8.27M-$8.27MN/M vs Q3 2020 EPS Diluted-$0.57-$0.57N/M vs Q3 2020 Gross Profit$4,602,000+40.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,630,000N/M Free Cash Flowderived-$6,921,000N/M Margins · derivedGross margin60.1%−1.7 pt vs Q3 2020
Operating margin-94.3%+34.9 pt vs Q3 2020
Net margin-108.0%+37.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end